MSB 0.92% $1.08 mesoblast limited

Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA, page-548

  1. 2,619 Posts.
    lightbulb Created with Sketch. 1659
    Hi JB1975- you refer to EAP patients and confounding variables. My understanding is that the new potency data is generated only from the 001 clinical trial- which removes the confounding variables. If Si was allowed to submit real world evidence from EAP patients I can see your point. But I think it is purely potency data from an assay that was in place at the time the 001 trial was conducted.

    The trouble is (one of them - there are probably about three at least) EAP patients are treated at physician discretion - and physicians tend to treat their patients differently from one to another which introduces confounding variables.



    Reg

    Last edited by reginaldp: 11/04/24
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.08
Change
-0.010(0.92%)
Mkt cap ! $1.233B
Open High Low Value Volume
$1.10 $1.11 $1.05 $5.002M 4.632M

Buyers (Bids)

No. Vol. Price($)
2 5697 $1.08
 

Sellers (Offers)

Price($) Vol. No.
$1.09 1000 1
View Market Depth
Last trade - 16.10pm 14/06/2024 (20 minute delay) ?
Last
$1.09
  Change
-0.010 ( 0.10 %)
Open High Low Volume
$1.09 $1.11 $1.06 1181223
Last updated 15.59pm 14/06/2024 ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.